Evaluation of Some Phenolic Acids in Diabetic Neuropathy

Shubhangi Pawar1,*, Aman Upaganlawar2, Chandrashekhar Upasani2

1Department of Pharmacology, MGV’s Pharmacy College, Panchavati, Nashik, Maharashtra, INDIA.
2Department of Pharmacology, SNJB’S SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, INDIA.

ABSTRACT

Background: Streptozotocin (STZ) induced neuropathy is widely used preclinical model for diabetic neuropathy (DN). DN is majorly resulted due to nitrosative and oxidative stress induced by hyperglycemia. Phenolic acids are polyphenols with free radical scavenging anti-inflammatory and neuroprotective action. Methods: In this study STZ (55mg/kg, i.p) was administered in male Wistar rats and animals with hyperglycemia (fasting blood glucose ≥ 200mg/dl) were used for further study. Behavioural changes cold allodynia, mechanical hyperalgesia, heat hyperalgesia, mechanical allodynia were assessed weekly. Motor Nerve Conduction Velocity (MNCV) was also evaluated. Reduced Glutathione and Malondialdehyde were estimated to indicate oxidative stress. C-Reactive Protein (CRP), Insulin assay, serum electrolytes (Na+, K+), TNF-α, IL-6 and INF-γ were also estimated. Isolated sciatic nerve was histopathologically studied to support the results. Results: Treatment with syringic acid (SY) 12.5, 25, 50 mg/kg and of Sinapic acid (SP) 5, 10, 20 mg/kg orally for 5 weeks has shown to reduce blood glucose level. Behavioural changes were found to be improved weekly by SY and SP in dose dependent manner. 5 weeks treatment with SY and SP was able to increase antioxidant GSH and reduce MDA level in cell. Gabapentin, SY and SP treated animals have shown decrease in TNF-α, IL-6 and INF-γ and CRP. Insulin and serum electrolytes were found to be normalised in treated groups. Histopathological study has revealed protective effect of gabapentin, SY and SP by showing reverted neuronal damage. Conclusion: In conclusion, syringic acid and sinapic acid have antihyperglycemic, antioxidant and neuroprotective effect in diabetic neuropathy.

Key words: Phenolic acids, Neuropathy, Hyperalgesia, Allodynia, Nerve conduction velocity, Antioxidants, Cytokines.

INTRODUCTION

Streptozotocin (STZ) is well established and reliable to induce diabetic neuropathy. STZ is nitrosoureas antibiotic used as anticancerant. STZ selectively destructs pancreatic β cells at dose of 45 to 70 mg/kg (i.v or i.p) and after 3-4 days, in rats causes hyperglycemia to induce diabetes.1 Diabetic neuropathy is majorly resulted due to nitrosative and oxidative stress induced by hyperglycemia. Thus formed reactive oxygen species (ROS) can cause sensory and motor nerve conduction defects.2 In animal models of diabetes mellitus (DM), STZ is suitably used to study disease pathogenesis and its complications.3

As modern medicines prominently show adverse effects, natural drugs are safer therapeutic alternative to treat neuropathy. Various plants and their phytoconstituents are selectively studied in the treatment of neuropathy in rats.4 Phenolic acids are polyphenols, having anti-inflammatory and free radical scavenging action, have been proven as neuroprotective.5 In accordance with these effects of various phenolic acids, unravelled members of this class can be evaluated through rational research plan. Syringic acid (SY) is useful in treatment of diabetes, cardiovascular diseases, cancer and cerebral ischemia. It is having antioxidant,
anti-microbial, anti-inflammatory, neuroprotective and hepatoprotective activities. It effectively scavenges free radicals and reduces oxidative stress markers. Sinapic acid (SP) is widely used in pharmaceutical and cosmetic industries because of its potent antioxidant, anti-inflammatory, preservative and antimicrobial activity. SP is effectively proven to prevent memory loss, counterbalancing oxidative stress and beneficial in the treatment of Alzheimer’s disease. So the present study was undertaken to evaluate effect of SY and SP in diabetic neuropathy.

MATERIALS AND METHODS

Syringic acid and sinapic acid purchased from sigma Aldrich, USA. Ketamine (Ketamax 50) from Troikaa Pharmaceuticals, India, Xylazine (Xylaxin) from Indian Immunologicals Ltd. India and Oxytetracycline ((Terramycin) Pfizer, India. Standard drug gabapentin was supplied by Sun Pharma, India.

Research proposal was prepared as per guidelines of CPCSEA and granted approval by Institutional Animal Ethical Committee (IAEC) of SNJB’s SSDJ College of Pharmacy, Chandwad, India (CPCSEA approval letter No. SSDJ/IAEC/2018/01).

Acute oral toxicity study was conducted as per OECD guidelines 425, Up and Down procedure. No any death observed after administration of oral dose of 2000mg/kg 5 female rats. So LD$_{50}$ is concluded more than 2000mg/kg. From the literature survey, minimum therapeutic doses of Syringic acid were finalised as 12.5, 25, 50 mg/kg/day and of Sinapic acid as 5, 10, 20 mg/kg/day orally. Standard drug gabapentin 300 mg/kg/day p.o. was used to compare the results.

Animals used were Wistar rats of either sex and divided into 9 groups (n=6) and treated for 5 weeks as followings:

1. Negative Control: received vehicle only.
2. Positive Control: STZ (55mg/kg, i.p.)
3. SY1: STZ (55mg/kg, i.p.) + Syringic acid 12.5mg/kg/day
4. SY2: STZ (55mg/kg, i.p.) + Syringic acid 25mg/kg/day
5. SY3: STZ (55mg/kg, i.p.) + Syringic acid 50 mg/kg/day
6. SP1: STZ (55mg/kg, i.p.) + Sinapic acid 5mg/kg/day
7. SP2: STZ (55mg/kg, i.p.) + Sinapic acid 10mg/kg/day
8. SP3: STZ (55mg/kg, i.p.) + Sinapic acid 20 mg/kg/day
9. Std: STZ (55mg/kg, i.p.) + Gabapentin 300 mg/kg/day p.o.

STZ dose in the range of 45 to 70 mg/kg develop type I DM in mammals but lower doses of STZ induce DM which may not stable and recovery from hyperglycaemia may occur. Additionally, if higher dosages are used, the death rate is found to be increased significantly. Extended research on pathological changes of DM, investigators specifically require a stable experimental model of type I DM. This tends to approach of dose standardization in experiment model, to choose appropriate dose of STZ which ensures minimum incidences of death and high incidences of DM. Thus in this project, from observations of pilot study, selected dose of STZ is 55mg/kg, i.p.

Induction of diabetes: STZ (55mg/kg, i.p.) dissolved in freshly prepared 0.001 M Citrate buffer, PH 4.5. After 72 hr, animals with remarkable hyperglycemia (fasting blood glucose ≥200mg/dl) were selected and used for further study.

Blood glucose levels: Blood glucose was monitored by using glucometer (Accu-check) to confirm hyperglycaemia. Blood glucose was measured at 72 hr and weekly thereafter till the end of treatment.

Behavioural study: In diabetic neuropathy behavioural biomarkers such as dysesthesia, hyperalgasia, allodynia and with motor in co-ordination are used to characterize peripheral nerve injury. a) Mechanical Allodynia (Von Frey test): Individually, rats were placed on elevated maze in acrylic cage and adopted for test environment for at least 15min. From below the mesh floor, Von Frey filament was applied to the planter aspect of right hind paw. Enough force of filament was applied against paw (causing slight bending) and hold for sec. Application of varying force (gm) repeated 6 times at interval of 4-5 sec. Withdrawal of paw was considered as a positive response. b) Cold Alldynia (Cold plate test): Here, the rodent was placed on the cooled plate at desired temperature (5°C) and the time to induce nociceptive behaviour indicated by shivering and paw licking was recorded as the response time. c) Mechanical Hyperalgnesia (Randall Sellitto method): Randall Selitto test is commonly used for testing acute mechanical sensitivity, measured by paw withdrawal threshold. Through the dome-shaped plastic tip of this apparatus, steadily increasing pressure applied on dorsal surface of the rat’s hind paw. The withdrawal threshold (in % CBK) for each paw was recorded. Measurements repeated 2 or 3 times on each paw. Animal was held to immobilize it. Place gently the paw on the apparatus and allow the tip of device to apply on paw with application of increasing mechanical force.
and withdrawal latency to the pressure supported was noted down.17

**d) Heat hyperalgesia (Hot plate test):** Eddy’s hot-plate was used to study the thermal nociceptive threshold by keeping the temperature at 55± 2°C. Animal individually tested by placing on the hot plate and paw licking latency (sec.) was recorded. Test cut-off time of 20 sec was maintained.18

**Evaluation of Motor Nerve Conduction Velocity (MNCV):** MNCV recording were carried out at the end of treatment. Animals were anesthetized by Ketamine (90mg/kg i.p) and Xylazine (5mg/kg i.p). MNCV assessment was done by using 8 channel powerlab (AD Instruments) with animal nerve stimulating electrode (MLA0320) and needle electrodes (MLA1204). Action Potential was generated by applying stimulating electrode at proximal end and recording done from distal end. (PowerLab setup as frequency: 10Hz, duration: 0.1ms, amplitude: 4V). The distance between the stimulating electrode and recording electrodes divided by latent period is calculated as conduction velocity. Latent period considered as the time between applications of stimulus until the peak of the action potential.19

On Next day, before scarification, animals were anesthetized lightly with ketamine for retro-orbital collection of blood in different tubes. Serum and plasma separated for electrolyte and cytokine estimation.

**Antioxidant study**

**a) Preparation of tissue homogenate:** After scarification sciatic nerve isolated and homogenized in ice cold TrisHCl buffer (10mM, 10% w/v). Centrifugation (using Remi C-24 high speed cooling centrifuge) carried out at 10,000 rpm for 15 min. Clear supernatant was used for further estimations.11

**b) RGSH (Reduced Glutathione):** It is determined by DTNB reagent method. The colour intensity developed was measured at 412nm against reagent blank.20

**Oxidative stress determination: MDA (Malondialdehyde):** It is determined by TBARS method. Absorbance of organic phase recorded at 535nm.21

**Histopathology:** Isolated sciatic nerve was kept in the 10% formalin and sent for study in pathology lab.22

**C-reactive protein (CRP):** It is determined by immunoenzymatic method.

**Insulin Assay:** Serum insulin (µIU/mL) is determined by CLIA method.

**Serum electrolytes:** Serum sodium (Na⁺) and potassium (K⁺) levels (mmol/L) are determined by direct ion selective electrode method.

**TNF-α, IL-6 and INF-γ:** It is estimated by MACSplex cytokine 12 kit, developed for the simultaneous flow Cytometric detection of cytokines.

**RESULTS AND DISCUSSION**

DN is a common as well as most concerned complication, occurring in almost 50 % of diabetes patients. Round about 10 to 20 % of diabetic population may experience painful symptoms and 40 to 50 % of them with DN experience chronic pain of neuropathy.23

Within 72 hrs of STZ injection, animals show hyperglycemia and lowered insulin secretion. STZ treatment exhibit behavioural signs of DN i.e. reduction in mechanical pressure withdrawal threshold and thermal withdrawal latency after about 2 weeks of injection.23

**Blood glucose level:** After 72 hr. of STZ injection, blood glucose level was found to be increased significantly in all treatment groups. Treatment with syringic acid 12.5, 25, 50 mg/kg and of Sinapic acid 5, 10, 20 mg/kg orally for 5 weeks has shown to reduce blood glucose level. SY1, SP1, std drug reduced it but statistically non-significant. SY2 and SP2 effect is with \( p<0.05 \)* and i.e. of SY3 and SP3 with \( p<0.01 \)**. Thus, syringic acid and sinapic acid have shown anti-hyperglycemic effect (Figure 1).

**Mechanical allodynia (Von Frey test):** Allodynia term refers to pain due to normally non noxious stimuli. It approximately occurs in 30–50 % of diabetic patients. This can be studies in STZ induced animal model, where nociceptive behaviour can be provoked by minimum force of Von Frey filaments to the paw (maximum upto15 g). Nitrosative stress, poly (ADP-ribose) polymerase (PARP) activation, increased excitability of ganglion neurons were thought to be associated with allodynia.25

Observations of mechanical allodynia are noted with 6 repeated application of varying force of Von Frey filament. Observations are recorded in the format of OXXOXO, where O indicated- no withdrawal response and X indicates withdrawal response.24 It is observed in positive control group that hyperalgesia is produced from 1st week indicated by withdrawal response to minimum force of filament. Treatment with SY and SP has shown to increase the threshold and force giving withdrawal response is found to be increased in dose dependent manner with change in observation format.
Cold Allodynia (Cold plate test): Paw withdrawal latency from cold plate (5°C) is found to be decreased in positive control group than negative control group. Symptoms of cold allodynia were observed from 3rd week of diabetes. SY1 (p<0.05*), SY2, SY3 and SP1, SP2, SP3 and Std drug gabapentin decreased cold allodynia with p<0.01** (Figure 2). These test drugs have shown protective effect from 1st week of treatment.

Mechanical hyperalgesia (Randall Selitto test): STZ induced diabetic animal model is widely accepted for study of mechanical hypersensitivity. An increased withdrawal threshold after mechanical pressure was considered to be associated with aldose reductase (AR) and oxidative stress. Withdrawal threshold of paw pressure is measured in terms of %CBK by Randall-Selitto apparatus. %CBK is found to be decreased in positive control group from 3rd week of diabetes induction. 5 week treatment with SY1, SY2 and SP1, SP2 has shown protective effect (p<0.05*) indited by dose dependent increase in %CBK and SY3, SP3 with p<0.01** (Figure 3). All observations are compared with standard gabapentin (p<0.01**).

Heat hyperalgesia (Hot plate test): It is an indicative of thermal hypersensitivity, which probably due to nociceptors or peripheral nerves damage. In STZ induced DN, mechanisms of thermal hyperalgesia are considered as increased oxidative stress and increased activity of protein kinase C (PKC), aldose reductase (AR), poly (ADP-ribose) polymerase (PARP), angiotensin converting enzyme (ACE) and toll-like receptor 4.23 Paw withdrawal latency and jumping response was observed after placing animal on preheated plate (55°C). Thermal hyperalgesia is found to be produced in positive control group from 2nd week of diabetes. Treatment with SY and SP has prevented thermal hyperalgesia from 1st week of treatment. After 5 weeks treatment SY2, SY3, SP1, SP2, SP3 and std drug shown significant protection (p<0.01**) of thermal hypersensitivity.
hyperalgesia. SY1 has shown protection but statistically non-significant (Figure 4).

**Motor Nerve Conduction Velocity (MNCV):** After completion of 5th week’s treatment, MNCV (m/sec) was measured. Positive control animals have shown marked reduction in conduction velocity compared to negative control animals. This indicates neuronal damage which is protected in treatment groups. Treatment with SY1, SP2 ($p<0.05$) SY2, SY3, SP3, std has prevented this damage and shown to increase conduction velocity (with $p<0.01$) than positive control group. SP1 dose have increased MNCV but statistically non-significant (Figure 5).

Abnormalities in motor nerve conduction are associated with reduction in neuronal blood flow induced by hyperglycemia and such resultant endoneural hypoxia lead to development of diabetic neuropathy.

**Oxidative stress (MDA):** Malondialdehyde (MDA) was measured from sciatic nerve tissue homogenate and absorbance recorded at 535 nm. Oxidative stress is found to be increased in positive control group indicated by increased absorbance. The MDA absorbance of positive control was considered as 100% (i.e. 0% inhibition of MDA) and comparatively % inhibition calculated for test and standard groups. Absorbance is comparatively decreased and % inhibition is increased significantly by SP1 ($p<0.05$) and in SY3, SP2, SP3 and standard group with $p<0.01$. (Figure 6). SY1 and SY2 have shown statistically non-significant effect. This indicated that SY and SP are able to reduce oxidative stress, in dose dependant manner, generated by STZ in neuropathy.

**Antioxidant (GSH):** It is abundantly available cellular antioxidant. In diabetes hyperglycemia induces glutathione (GSH) depletion and impaired regeneration which links to diabetic neuropathy like complications.

After STZ injection and neuropathy development GSH level is found to be decreased in positive control group indicted by significant decrease in absorbance at 412 nm. This absorbance is increased in treatment group’s dose dependently. % increase in GSH level is calculated by considering 100% GSH level of negative control and 0% in positive control group. This study indicates 5week treatment with SY and SP (SY2, SP2 with $p<0.05$) is able to increase antioxidant GSH level in cell (Figure 7). A dose of SY1 and SP1 increased GSH level statistically non-significant. SY3, SP3 and std drug improved GSH with $p<0.01$.

Thus, STZ induced DN is widely studied animal model. Possibly responsible mechanisms for hyperalgesia and abnormal sensation are increased oxidative-nitrosative stress and AR, PKC, PARP and ACE activations. It may also be associated with C-peptide deficiency, impaired neurotrophism and proinflammatory response.
C-reactive proteins (CRP): CRP is an important pro-inflammatory factor, regulated by interleukin-6, interleukin -1 and TNF-α. During inflammation, it is produced by the liver.\(^\text{27}\) It is determined by immunoenzymatic method. It is found that serum CRP is comparatively enhanced in positive control group than negative control, indicating possibility of neuronal damage and neuroinflammation. 5 weeks treatment with SY2, SY3, SP2, SP3 and Std gabapentin reduced CRP with \(p<0.01**\). SY1 and SP1 have shown statistically non-significant protective effect indicated by decrease in CRP compared to positive control group (Figure 8).

**Insulin Assay:** Serum insulin (µIU/mL) is determined by CLIA method. In positive control animals insulin level is found to be decreased significantly indicating damage to β pancreatic cells. This is also indicated by severe hyperglycaemia. Blood sugar level is found to be controlled by treatment with SY and SP supported by rise in serum insulin level (\(p<0.05^*\)). SP1 gives non-significant increase and SY3 shown increase with \(p<0.01**\). Thus 5 weeks treatment with SY and SP has shown protective effect on β pancreatic cells (Figure 9).

**Tumour Necrosis Factor-α, Interleukin-6 and Interferon-γ:** STZ-injected diabetic rats had significantly increased IL-6, TNF- α and INF- γ as compared to negative control rats. Gabapentin, SY and SP treatment have shown significant (\(p<0.01**\)) decrease in IL-6, TNF- α and INF- γ (Figure 10). Inflammatory pathology in diabetes can be confirmed by increase in infiltration of inflammatory cells and changes in cytokines levels.\(^\text{29}\) Oxidative stress causes production of abnormal cytokine production (TNF-α, IL-6 and INF-γ).\(^\text{27}\) Previous studies reported direct inter-relation of TNF-α, IL-1and IL-6 with insulin. Also, it is suggested that inflammation can directly cause insulin resistance. TNF-α decreases insulin secretion by causing inflammation.\(^\text{27}\)

**Serum electrolytes:** Serum electrolyte level is changed with plasma glucose level. Electrolyte balance is disturbed with diabetes mellitus. Consistent hyperglycaemia can damage Na\(^+\)-K\(^+\) ATPase and other ATPase pumps and causes reduction in serum Na\(^+\) level.\(^\text{29}\) Serum sodium (Na\(^+\)) and potassium (K\(^+\)) levels (mmol/L) are determined by direct ion selective electrode method at Apollo diagnostic lab. Comparatively serum Na\(^+\) level is found to be decreased and K\(^+\) level is increased in positive control animals than negative control. 5 weeks treatment with SY and SP have reversed the effect by increasing serum Na\(^+\) (\(p<0.01**\)) and decreasing K\(^+\) (SY1 statistically non-significant, SP1, SP2 with \(p<0.05^*\) and SY2, SY3, SP3 and std with \(p<0.01**\)) level indicating its neuronal protective effect (Figure 11).

**Histopathology:** Histopathology Section of H and E stained sciatic nerve of diabetic control rats showed epineuronal oedema and infiltration of neutrophils around blood vessels and swelling of nerve fibres.
Antioxidant and anti-inflammatory action.

From above results, it can be concluded that Syringic acid and Sinapic acid have neuroprotective role in diabetic neuropathy. This effect may be attributed to their anti-hyperglycemic, anti-hyperalgesic, antioxidant and anti-inflammatory action.

ACKNOWLEDGEMENT

Authors are thankful to trust of MGV and SNJB for providing necessary laboratory facilities.

CONFLICT OF INTEREST

The authors do not have any conflict of interest.

ABBREVIATIONS

DN: Diabetic Neuropathy; STZ: Streptozotocin; DM: Diabetic Mellitus; SY: Syringic acid; SP: Sinapic acid; MNCV: Motor Nerve Conduction Velocity; MDA: Malondialdehyde; GSH: Glutathione; CRP: C-Reactive protein; TNF: Tumour Necrosis Factor; INF: Interferon.

REFERENCES

In the present study, STZ have induced neuropathy symptoms in 3rd week in positive control group. 5 weeks treatment with SY and SP has found to protect behavioural changes by reducing mechanical allodynia, thermal hyperalgesia and mechanical hyperalgesia. Oxidative stress and antioxidants enzyme level in also found to be protected in treated groups in dose dependant manner. Nerve conduction velocity was decreased in positive control group due to neuronal hypoxia produced by hyperglycemia. This was significantly improved by treatment with SY and SP. Markers of neuroinflammation i.e. C reactive protein, Interleukin-6, TNF-α and INF-γ were found to be increased in positive control group after STZ. These cytokine levels were found to be decreased in positive control group after STZ. These cytokine levels were found to be decreased in positive control group after STZ. Thus, from this result, it is concluded that Syringic acid and Sinapic acid have neuroprotective role which may be attributed to their anti-hyperglycemic, anti-hyperalgesic, antioxidant and anti-inflammatory action. So these natural phenolic acids syringic acid and Sinapic acid can be therapeutically used in combination with current treatment of diabetic neuropathy.

Cite this article: Pawar SH, Upaganlawar AB, Upasani CD. Evaluation of Some Phenolic Acids in Diabetic Neuropathy. Indian J of Pharmaceutical Education and Research. 2021;55(1s):s176-s183.